Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

66P - Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese Patients

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Zhijie Wang

Citation

Annals of Oncology (2020) 31 (suppl_7): S1441-S1451. 10.1016/annonc/annonc392

Authors

Z. Wang1, J. Zhao2, Z. Ma3, J. Cui4, Y. Shu5

Author affiliations

  • 1 National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing/CN
  • 2 Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing/CN
  • 3 Henan Cancer Hospital, Zhengzhou/CN
  • 4 First Hospital of Jilin University, Changchun/CN
  • 5 Jiangsu Province Hospital, Nanjing/CN
More

Abstract 66P

Background

Tislelizumab, an anti-PD-1 antibody, was engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. In previous reports, tislelizumab was generally well tolerated and had antitumor activity in patients with advanced solid tumors.

Methods

This phase II study (BGB-A317-206; NCT03432598) assessed tislelizumab (200 mg Q3W) + platinum (plat)-based chemotherapy (Q3W) as first-line treatment for Chinese patients with advanced lung cancer. All patients received tislelizumab + plat doublet chemotherapy. Non-squamous (NSQ) NSCLC patients received plat + pemetrexed (PMX) for 4 cycles followed by PMX maintenance. Squamous NSCLC patients received 4-6 cycles of plat + paclitaxel (SQ-A) or plat + gemcitabine (SQ-B); SCLC patients received plat + etoposide. Response rate (RECIST v1.1), progression-free survival (PFS), overall survival (OS), and safety/tolerability were evaluated.

Results

As of 31 Dec 2019, 54 patients (median age 61 yr; 74% male; 72% current/former smokers) received tislelizumab + chemotherapy. Median follow-up ranged from 15.5 (SCLC) to 25.3 mo (SQ-B). Response and survival are shown in the Table. Median PFS was 6.9 mo, 7.0 mo, 9.0 mo, and NE for the SCLC, SQ-A, NSQ, and SQ-B cohorts, respectively. Median OS was only reached in the SCLC cohort (15.5 mo; 95% CI: 11.8, NE). The most common grade ≥3 adverse events (AEs) were decreased neutrophil count (n=26) and anemia (n=10). Immune-related AEs were reported in 18 patients. One SQ-A patient experienced myocarditis with a fatal outcome after 1 tislelizumab dose. Table: 66P

NSQ (n=16) SQ-A (n=15) SQ-B (n=6) SCLC (n=17)
Median study follow-up, mo 23.0 24.2 25.3 15.5
Confirmed partial response, n 7 12 4 13
Stable disease, n 8 2 1 2
Progressive disease, n 1 0 0 1
Missing, n 0 1 1 1
ORR, % (95% CI) 44 (20, 70) 80 (52, 96) 67 (22, 96) 77 (50, 93)
DCR, % (95% CI) 94 (70, 100) 93 (68, 100) 83 (36, 100) 88 (64, 99)
OS rate at 24 mo, % (95% CI) 51 (23, 74) 65 (35, 84) 80 (20, 97) 31 (10, 55)
Median PFS, mo (95% CI) 9.0 (4.3, 21.4) 7.0 (5.5, 18.6) NE (4.3, NE) 6.9 (4.9, 10.1)

Abbreviations: CI, confidence interval; DCR, disease control rate; NE, not estimable; ORR, objective response rate.

Conclusions

In this phase II study, tislelizumab plus plat-based chemotherapy, as first-line treatment for advanced lung cancer, demonstrated preliminary antitumor activity including 24-mo OS rates of 51%, 65%, 80%, and 31% for patients in the NSQ, SQ-A, SQ-B, and SCLC cohorts. No new safety signals were identified.

Clinical trial identification

NCT03432598.

Editorial acknowledgement

Writing and editorial assistance was provided by Stephan Lindsey, PhD, and Elizabeth Hermans, PhD (OPEN Health Medical Communications, Chicago, IL), and funded by the study sponsor.

Legal entity responsible for the study

BeiGene, Ltd.

Funding

BeiGene, Ltd.

Disclosure

S. Leaw: Shareholder/Stockholder/Stock options, Full/Part-time employment: BeiGene, Ltd. Y. Wu: Shareholder/Stockholder/Stock options, Full/Part-time employment: BeiGene, Ltd. Y. Ma: Shareholder/Stockholder/Stock options, Full/Part-time employment: BeiGene, Ltd. W. Tan: Shareholder/Stockholder/Stock options, Full/Part-time employment: BeiGene, Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings